I am surprised that ACU has not been able to trade at higher levels. Credentials of all involved at the Research Institute are very good. We have to remember that it was the institute that developed the new test, not ACU. Unfortunately another company, Visiomed, which also has an association with the same institute has not been a good market performer recently. Research takes such a long time and is very expensive with no guarantee of success. There could be a worry among shareholders and potential investors that the company may need to raise more money to fund this alliance. No financial details of the agreement have been given as far as I know, and, until they are, I prefer to sit on the sidelines.
ACU Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
